Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
Pre-Tax Income
Ocular Therapeutix Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Pre-Tax Income
-$193.5m
|
CAGR 3-Years
-209%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-21%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$26.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
-$8.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
$8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$19.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
23%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$12.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
16%
|
|
Ocular Therapeutix Inc
Glance View
Ocular Therapeutix Inc., nestled in the bustling biotechnology hub of Bedford, Massachusetts, is forging a new path in the ophthalmic treatment landscape. At its core, the company's mission pivots on the innovation and commercialization of novel therapies that address significant unmet needs in eye care. By leveraging its proprietary hydrogel technology, Ocular Therapeutix has developed a rich pipeline of both drug delivery and ophthalmic surgical products. Its flagship product, DEXTENZA, stands as a beacon of its innovative approach, offering an alternative to traditional drug delivery methods by releasing medication directly to the target site through a bioresorbable hydrogel implant. This targeted drug delivery not only enhances treatment efficacy but also addresses the age-old challenge of patient compliance in eye care, providing a significant competitive advantage in the market. Financially, Ocular Therapeutix develops its sustainability through a multi-pronged strategy that involves direct sales, licensing agreements, and strategic partnerships. Revenue is primarily generated from sales of its marketed products and milestones achieved through partnerships with other pharmaceutical companies. DEXTENZA and the upcoming products from its pipeline continue to chart new territory in securing market share by offering superior clinical outcomes. The company’s innovative technologies also open doors for licensing deals, providing a steady revenue stream as they partner with global firms that recognize the potential of personalized ophthalmic care. By threading together scientific innovation, strategic commercialization, and robust industry partnerships, Ocular Therapeutix positions itself not just as a biotech company, but as a transformative player aiming to redefine the ophthalmic treatment paradigm.
See Also
What is Ocular Therapeutix Inc's Pre-Tax Income?
Pre-Tax Income
-193.5m
USD
Based on the financial report for Dec 31, 2024, Ocular Therapeutix Inc's Pre-Tax Income amounts to -193.5m USD.
What is Ocular Therapeutix Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-21%
Over the last year, the Pre-Tax Income growth was -140%. The average annual Pre-Tax Income growth rates for Ocular Therapeutix Inc have been -209% over the past three years , -18% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet